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Summary 34 
The H3K27 lysine-specific demethylase UTX is targeted by loss-of-function mutations in multiple 35 
cancers. Here, we demonstrate that UTX suppresses myeloid leukemogenesis through non-catalytic 36 
functions, a property shared with its catalytically inactive Y-chromosome paralogue, UTY. In keeping 37 
with this, we demonstrate concomitant loss/mutation of UTX and UTY in multiple human cancers. 38 
Mechanistically, global genomic profiling revealed only minor changes in H3K27Me3, but significant 39 
and bidirectional alterations of H3K27Ac and chromatin accessibility, a predominant loss of 40 
H3K4Me1 modifications, alterations in ETS and GATA factor binding and altered gene expression 41 
upon Utx loss. By integrating proteomic and genomic analyses, we link these changes to UTX 42 
regulation of ATP-dependent chromatin remodeling, coordination of the COMPASS complex and 43 
enhanced pioneering activity of ETS factors during evolution to AML. Collectively, our findings reveal 44 
a dual role for UTX in suppressing acute myeloid leukaemia via repression of oncogenic ETS and 45 
upregulation of tumor-suppressive GATA programs.  46 
Introduction 47 
Enzymatic modifications of histones play a central role in the control of gene expression to 48 
orchestrate diverse biological processes1. The JmjC-domain-containing protein ubiquitously 49 
transcribed tetratricopeptide repeat, X-linked  (UTX or KDM6A), which demethylates di- and tri-50 
methylated lysine-27 of histone H3 (H3K27Me3)2, is a frequent target of somatic loss-of-function 51 
mutations in multiple cancer types3,4,5,6,7,8 including leukemia9-12. Re-introduction of intact UTX into 52 
mutation-bearing cancer cells leads to significant transcriptional changes and a reduction in 53 
proliferation7 in keeping with its role as a tumor suppressor, however the mechanism whereby UTX 54 
suppresses malignancy are poorly studied. Mechanistic insights into the tumor suppressive function 55 
of UTX have come from studies of T-cell acute lymphoblastic leukaemia (T-ALL) where an absence of 56 
UTX-catalytic function is pivotal for T-ALL initiation and maintenance9. Importantly, UTX mutations in 57 
T-ALL are almost exclusively found in males, reflecting the fact that the gene is X-linked and escapes 58 
X-inactivation13, such that females (but not males) with single allele loss-of-function UTX mutations 59 
retain UTX expression14. Interestingly, in T-ALL mutations are concentrated in the catalytic JmjC 60 
domain, whereas this bias is not seen in other cancers where the mutations are spread throughout 61 
the gene15, raising the possibility of different tumor suppressive mechanisms. Of potential relevance, 62 
UTY (KDM6C), the Y-chromosome homologue of UTX, has markedly reduced demethylase activity 63 
due to point substitutions affecting substrate-binding16. By contrast, in common with UTX, UTY 64 
contains an intact tetratricopeptide repeat region involved in protein-protein interactions that 65 
mediate demethylase-independent functions17. Tantalizingly, deletion of UTY was seen more 66 
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frequently than expected in cancer cell lines with mutations in UTX, than in those without7, raising 67 
the possibility of a functional redundancy between the two paralogues. 68 
Using myeloid malignancies as an exemplar, we investigate the role of UTX loss in oncogenesis and 69 
its interaction with UTY in mice following haematopoietic-specific loss of Utx. Our findings reveal 70 
that UTX prevents leukemogenesis by coordinate repression of pro-oncogenic ETS (E-twenty-six) and 71 
maintenance of tumor-suppressive GATA transcriptional programs. These effects are mediated by 72 
differential effects on genome-wide H3K27 acetylation, H3K4 monomethylation and chromatin 73 
accessibility, and their functional consequences were rescued by both UTY and enzymatically dead 74 
UTX, confirming their independence of demethylase activity.       75 
  76 
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Results 77 
Homozygous loss of Utx induces spontaneous leukemia in a murine model. 78 
To investigate the function of UTX in the hematopoietic system, we generated conditional Utx 79 
knock-out mice, where exon 3 of Utx is flanked with loxP sites (Utxf/f)18 (Fig.1a). Utxf/f mice were 80 
crossed into the inducible Mx1-Cre line, enabling efficient Utx recombination in hematopoietic stem 81 
and progenitor cells (HSPC) following polyinosinic-polycytidylic acid (pIpC) administration that 82 
activates the Mx1-promoter. Utxf/f;Mx1-Cre mice treated with pIpC (hereafter Utx-/-) showed loss of 83 
Utx mRNA and protein (Fig.1b-c) compared to pIpC-treated Utxf/f mice (hereafter Utx+/+/WT). Female 84 
Utx-/-, Utx+/- and Utx+/+ mice were then aged and monitored for leukaemia development for up to 22 85 
months. Utx-/- mice demonstrated significantly decreased survival in comparison to Utx+/- and Utx+/+ 86 
female mice (Fig.1d). At necropsy, Utx-/- mice had a significantly increased spleen weight (Fig.1e) and 87 
a predominance of myeloid cells in the spleen and bone marrow (BM) (Fig.1f). Blood leukocyte 88 
counts (WBC) showed a variable rise and both platelet (PLT) and hemoglobin (HGB) levels were 89 
decreased (Fig.S1 a-c). Histological examination revealed that the majority (63%) developed acute 90 
myeloid leukaemia (AML) (Fig.1g-h). In contrast, no Utx+/- or Utx+/+ mice developed AML. Splenocytes 91 
from leukaemic Utx-/- mice propagated the disease in secondary recipients (Fig.1i) verifying their full 92 
leukemogenic potential. Exome sequencing of seven Utx-/- AMLs showed no recurrently mutated 93 
genes, with the exception of Skint11 (2/7 samples), and only occasional copy number alterations 94 
(Fig.S1 d-f). To more accurately mimic human disease we expressed the AML1-ETO fusion gene that 95 
commonly co-occurs with UTX mutations10,19,20 in Utx-/- HSPC, and observed significantly reduced 96 
survival of recipient mice (Fig.S1 g-i).  97 
Deregulation of HSPC number, function and differentiation following Utx loss 98 
Our findings suggested that Utx loss confers a pre-leukaemic state on HSPCs, with transformation 99 
reliant on additional mutations. To characterize this pre-leukemic phase, we analyzed mice early 100 
after Utx deletion (4-5 weeks post-pIpC). As reported previously21, Utx-/- mice demonstrated splenic 101 
enlargement in comparison to Utx+/+ and Utx+/- mice (Fig.2a-b). We next examined the effect of UTX 102 
on hematopoietic differentiation and composition of the HSPC compartment, likely to harbor the 103 
initial target cell for transformation. Utx-/- mice demonstrated a significant expansion of HSPC 104 
progenitors (lineage negative, Lin-) (Fig.2c), long-term and short-term hematopoietic stem cell (LT-105 
HSC; ST-HSC) frequency (Fig.2d, Fig.S2a), an increase in the granulocyte–monocyte progenitor (GMP) 106 
and common myeloid progenitor (CMP) and a decrease in the megakaryocyte-erythroid progenitor 107 
(MEP) compartments (Fig.2e-f, Fig.S2b), as well as a significant reduction in common lymphoid 108 
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progenitors (CLP)(Fig.2g, Fig.S2c). To assess HSPC function, we performed serial re-plating assays, 109 
observing enhanced self-renewal and proliferative potential of Utx-/- progenitors (Fig.2h and 110 
Fig.S3a). As regards mature cell numbers in BM, spleen and blood, only peripheral blood (PB) 111 
thrombocytopenia was noted at 5 weeks post-pIpC (Fig.S3b-d). However, at later time points (36 112 
weeks post pIpC) in otherwise well animals, there was also an increase in PB MAC1+ myeloid cells 113 
and total WBC, and a reduction in B-cells in Utx-/- compared to Utx+/+ mice (Fig.S3e-g). Collectively, 114 
these results demonstrate that biallelic loss of Utx leads to dramatic and progressive alterations in 115 
the composition, function and differentiation of HSPCs and their progeny, including enhanced self-116 
renewal, myeloid expansion and a block in lymphoid and erythroid/megakaryocytic differentiation 117 
(Fig.2i).  118 
UTY also suppresses leukemia induction and rescues the UTX-deficient pre-leukemic phenotypes 119 
To define any role for UTY in suppressing leukemogenesis we also monitored hemizygous (Utx-/Y, 120 
lacking Utx but expressing Uty) and control (Utx+/Y) male mice over the same time period. 121 
Remarkably, and in stark contrast to Utx-/- females, Utx-/Y males showed no difference in survival or 122 
hematological phenotype compared to Utx+/Y mice (Fig.2j). In particular, we observed no differences 123 
in spleen and liver weights, WBC counts, platelet or hemoglobin levels (Fig.S3h-l). Also, no Utx-/Y 124 
mice developed AML, indicating that UTY also suppresses myeloid leukemogenesis (Fig.2k). Similarly, 125 
the presence of UTY in hemizygous males was sufficient to abrogate the abnormalities in pre-126 
leukemic HSPCs, apart from decreases in the MEP and CLP compartments (Fig.2l and Fig.S4a-i). 127 
Importantly, CRISPR/Cas9-mediated knockout of Uty in Utx-/Y mice increased HSPC self-renewal, 128 
phenocopying Utx-/- female mice (Fig.2m-n).  129 
As the only significant difference between UTY and UTX proteins is the lack of catalytic activity in the 130 
former, these findings suggested that catalytic activity is dispensable for their tumor suppressor 131 
functions. To further test this hypothesis, we identified an AML cell line, MONO-MAC6, with deletion 132 
of both UTX and UTY. Lentiviral expression of UTX, UTY or a catalytically-dead UTX mutant (UTX-133 
MT2)22 in MONO-MAC6 confirmed this hypothesis, with all constructs significantly suppressing 134 
proliferation in vitro (Fig.3a-c). In xenotransplant assays, MONO-MAC6 expressing UTX, UTX-MT2 or 135 
UTY demonstrated slower growth and a significant survival advantage over FLAG-expressing control 136 
cells (Fig.3d-f). Taken together these studies demonstrate that the tumor suppressor functions of 137 
UTX do not require its catalytic activity and are shared with its catalytically-inactive paralogue UTY. 138 
Concomitant loss of both UTX and UTY tumor suppression occurs in multiple human cancer types 139 
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Our findings indicate that UTY can suppress myeloid leukemogenesis, however unlike T-ALL14, UTX-140 
mutated AML cases show no gender bias. We therefore analysed the status of UTY in human male 141 
AML cell lines carrying UTX mutations, identified through the COSMIC database (Fig.3g). Of 4 male 142 
AML lines with UTX mutations/deletions, we confirmed loss of UTY expression in all 4 (Fig.3h). 143 
Analysis of exome sequencing data from COSMIC, revealed that all harbored a UTY microdeletion. 144 
Systematically extending our analysis, a further 7 male hematopoietic cell line with UTX mutations 145 
were identified, of which 4 had UTY microdeletions (TableS1). Strikingly, in informative solid organ 146 
cancers, 20/25 (80%) UTX-mutant male cell lines also demonstrated UTY microdeletion/mutation 147 
(TableS1), and we confirmed loss of UTY expression  in a subset (10/13, Fig.3i).  148 
Integrated genome-scale analysis identifies altered enhancer function as a mediator of 149 
leukemogenesis following Utx loss 150 
To determine the molecular basis of UTX-mediated leukemia suppression, we performed integrated 151 
genome-scale analyses (RNA-Seq, ChIP-Seq and ATAC-Seq) in HSPCs from age-matched pre-leukemic 152 
Utx-/-, Utx-/Y and Utx+/+ mice. As anticipated, in comparison to controls, the number of differentially 153 
expressed genes was significantly greater for Utx-/- than Utx-/Y (4497 vs 673 genes, P < 0.05; TableS2-154 
S4). As loss of their single Utx allele did not lead to AML in hemizygous Utx-/Y males, we removed 155 
these 673 genes from subsequent analysis. Focusing on mRNAs differentially expressed with a log2 156 
fold change > ±0.5, we identified 2686 genes (Fig. 4a-b). Interestingly, and somewhat 157 
counterintuitive to the perception of UTX as solely a transcriptional activator, similar numbers of 158 
genes were upregulated (1517, 57%) upon Utx loss, as were downregulated (1169, 43%). 159 
Importantly, although additional genes were also differentially expressed upon evolution to frank 160 
AML in Utx-/- mice, significant components of the pre-leukemic transcriptional programs were 161 
retained (Fig. 4c, TableS5). Using ChIP-Seq in WT mice, we documented 8304 UTX binding sites, 162 
corresponding to 6734 genes (TableS6), with the majority found at the promoter or within the gene 163 
body (Fig. 4d). Correlation with gene expression demonstrated that 581/1169 (50%) of 164 
downregulated and 614/1517 (40%) of upregulated gene loci were bound by UTX (TableS7), 165 
suggesting that around half of deregulated genes are direct UTX targets (Fig. 4e) and confirming UTX 166 
as both a transcriptional activator and repressor. 167 
In keeping with our finding that H3K27-demethylase activity is redundant for tumor suppression, 168 
only 302 differentially modified H3K27Me3 peaks were observed between Utx-/- and Utx+/+ HSPC . 169 
Further corroborating this notion, the majority (200/302, 67%) also showed decreased rather than 170 
increased modification (Fig. 4f, TableS8). In marked contrast, the coordinated acetyl modification at 171 
the same lysine residue, H3K27Ac, was markedly altered in its distribution in Utx-/- in comparison to 172 
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Utx+/+ mice. We observed 5121 regions with differential H3K27Ac in either direction (corresponding 173 
to 2916 gene loci), including 3442 peaks (2054 gene loci) significantly decreased and 1679 (953 gene 174 
loci) increased, following UTX loss (Fig.4g and Tables S9-S10). Comparing these putative enhancer 175 
regions to a recently published promoter-based capture-HiC dataset in the hematopoietic stem and 176 
progenitor cell line HPC723, we observed that 23% of upregulated and 32% of downregulated regions 177 
interacted with promoters (Fig.S5a-c), suggesting significant enhancer remodeling on UTX loss. The 178 
observed changes were locus-specific, as global levels of H3K27Ac and H3K27Me3 were similar 179 
between Utx+/+ and Utx-/- BM (Fig.S5d). In order to define direct co-occurrence on chromatin we 180 
overlapped UTX peaks and differential H3K27Ac regions. However, we found only a modest co-181 
occurrence, with just 282/5121 regions (6%) in common (Fig.S5e). UTX-peaks and differential 182 
H3K27Ac regions were then annotated to their associated/adjacent genes, defining larger genomic 183 
areas for comparison. In contrast to the limited peak-to-peak co-occurrence, when we compared 184 
whole gene loci showing differential H3K27Ac and UTX binding, we identified a highly significant 185 
overlap of 1396/2916 regions (48%, Fig.S5f, TableS11), suggesting that UTX indirectly regulates 186 
acetylation of regions adjacent to its binding. To further address the impact of UTX on enhancer 187 
function, we performed ChIP-Seq for the canonical enhancer defining mark H3K4Me1 in pre-188 
leukaemic Utx-/- and Utx+/+ HSPC. Of particular interest, H3K4Me1 is deposited by KMT2C/D, 189 
components of the COMPASS complex that are known UTX interaction partners24. We observed 190 
4552 differentially modified H3K4Me1 peaks (Fig. 4h; TableS12); of which the majority, 3898, were 191 
downregulated in Utx-/- mice. Differentially downregulated H3K4Me1 regions highly correlated with 192 
peaks that also lost H3K27Ac (1589 common peaks - 46% overlap). UTX did not bind directly at these 193 
sites, proposing an indirect role of UTX and the COMPASS complex in early enhancer specification. 194 
Taken together, these data confirm that H3K27 demethylase activity is dispensable for tumor 195 
suppression, identify UTX as both a transcriptional activator and repressor and suggest that 196 
UTX/COMPASS-mediated indirect regulation of enhancers is important for transformation.  197 
 198 
Loss of Utx activates an oncogenic ETS transcriptional program during leukemia development.  199 
As our genomic data demonstrated both loss and gain of activating chromatin marks and up- and 200 
downregulation of gene expression upon Utx loss, we speculated that both processes were 201 
necessary for leukaemia development, but may be mediated by different mechanisms. We therefore 202 
analysed up and down regulated gene programs separately. Notably, several ETS transcription 203 
factors, including Elf4, Etv6, Erg, Fli1, Ets2 and Elk were upregulated immediately following Utx loss 204 
in the pre-leukaemic phase (Fig.5a). Importantly, overexpression of these ETS factors persisted in 205 
Utx-/- AML (Fig.5b). GSEA analysis also demonstrated a significant correlation between upregulated 206 
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pre-leukaemic transcriptional programs and genes repressed upon knockdown of the oncogenic ETS-207 
factor fusion EWSR1-FLI1 (Fig.5c). In addition, motif analysis of 614 UTX-bound and upregulated 208 
genes demonstrated a significant enrichment in ETS binding motifs (Fig.5d, TableS30). To directly 209 
link an ETS program to leukemogenesis we mapped global chromatin occupancy of the ETS factor 210 
PU.1 in Utx-/- and Utx+/+ HSPCs. We observed 8329 enriched and 5869 depleted PU.1 peaks in Utx-/- 211 
(TableS13). Many ETS-factors overexpressed in Utx-/- and directly bound by UTX in wild type cells, 212 
including Ets2 and Fli1 showed higher PU.1 promoter occupancy in the absence of UTX (Fig.S5g). 213 
These data suggest enhanced ETS factor binding and transcriptional auto-regulation of specific ETS 214 
genes in the absence of Utx. On a global scale however, UTX binding did not co-localize with PU.1 215 
chromatin occupancy (only 115 peaks/14198, 0.8%), suggesting that the profound general 216 
redistribution of PU.1 binding may relate more to its overexpression. ETS factors are known to 217 
recruit histone acetyltransferases25, and thus increase H3K27Ac deposition, therefore we next asked 218 
if the changes in differential H3K27Ac and H3K4Me1 observed in Utx-/- correlate with UTX-219 
dependent redistribution of PU.1 binding. Indeed, we observed that 51% of gained H3K4Me1 220 
(335/654) and 30% of gained H3K27Ac (470/1679) peaks also demonstrated increased PU.1 binding 221 
(Fig.S6a-b). These direct binding data provide a mechanistic explanation for the gain of enhancer 222 
marks upon Utx loss.  223 
To investigate the functional significance of deregulated ETS factors we utilized CRISPR/Cas9 genome 224 
editing to ablate a number of these factors in Cas9-expressing, UTX/UTY mutant, MONO-MAC6 cells. 225 
Importantly, we observed significant growth suppression upon editing of the same ETS factors 226 
immediately overexpressed upon Utx loss: FLI1, ERG, PU.1, ETS1, and ELF4 (Fig.5e). These data 227 
conclusively indicate that ETS factors drive leukemia induction and maintenance in the context of 228 
UTX/UTY loss.  229 
Utx loss affects BRG1-dependent chromatin remodeling to repress a tumor suppressive GATA 230 
program during leukemia development.  231 
Analysis of the downregulated gene-expression program using GSEA, demonstrated enrichment for 232 
GATA2 targets (Fig.5f). Furthermore, motif analysis at the 3442 regions with significantly decreased 233 
H3K27Ac upon Utx loss demonstrated a striking and almost exclusive enrichment in GATA binding 234 
motifs (Fig.5g, TableS30). Similarly to the ETS motifs, loss of H3K27Ac did not directly overlap with 235 
UTX binding (Fig.S6c-d) but occurred nearby and likely affected the same genes (Fig.S6e, TableS14). 236 
To better understand the indirect effect of UTX on acetylation changes at GATA and ETS sites, we 237 
performed pulldown of endogenous UTX in the murine myeloid cell line 416B, followed by mass 238 
spectrometric analysis. We did not observe UTX interaction with ETS-factors or GATA2 but we did 239 
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identify multiple known UTX interactors, including KMT2C/D/COMPASS members (Fig.5h, Tables 240 
S15-S16). Interestingly, our proteomic analysis also demonstrated lower level interactions between 241 
UTX and the ATP-dependent chromatin remodeling complex members BRG1 (SMARCA4) and CHD4, 242 
which we further verified (Fig.S6f). Speculating that changes in acetylation and GATA binding 243 
occurred through alterations in chromatin accessibility, we performed ATAC-Seq analysis in pre-244 
leukaemic Utx-/- HSPC and Utx+/+ controls. Strikingly, we observed significant and bidirectional 245 
changes in chromatin accessibility, including 7200 sites where chromatin accessibility decreased and 246 
5244 sites that became accessible upon Utx loss (TablesS17-18). Loss of chromatin accessibility 247 
correlated strongly with decreased H3K27Ac (2274/3442 peaks, 73%) and H3K4Me1 deposition 248 
(2264/3898, 58%) (Fig.S7a,d) and decreased gene expression (Fig.S7b, TableS19). Furthermore, 249 
analysis of closed chromatin sites showed a striking enrichment in GATA motifs (Fig.6a, Fig.S7a-b). 250 
Comparisons of GATA2 peaks in HPC-726 with differential chromatin accessibility in Utx-/- HSPC 251 
demonstrated direct correlation only with closed chromatin regions (15%, 409/2796 peaks), as only 252 
0.7% (19/2796 peaks) overlapped with open chromatin. As before, only limited overlap was found 253 
between closed chromatin and UTX binding (Fig.S7c). We next asked if UTX binds with BRG1 and 254 
CHD4 on chromatin. Importantly, we observed a highly significant overlap, 91% (7541/8304 peaks) 255 
of UTX sites with binding of both BRG1 and CHD4 from published ChIP-Seq27 (Fig.6c-e). To validate 256 
co-occupancy we employed CRISPR/Cas9 genome editing of Utx in 416B cells targeting Utx exon-3, 257 
recapitulating our mouse model. We observed significantly lower chromatin binding for BRG1 and 258 
CHD4 at exemplar loci (Aff1 and Lrrc8c) in the absence of UTX, in keeping with a role for UTX in the 259 
recruitment of complexes containing these proteins (Fig.S7e-g). 260 
To further address molecular mechanism of UTX-dependent chromatin remodeling, we analysed the 261 
activity of BRG1 and CHD4 in Utx-/- and Utx+/+ HSPCs. We crossed Utxf/f;Mx1-Cre mice with Cas9-262 
expressing mice28 and induced Utx deletion. Five weeks post gene deletion we isolated HSPCs and 263 
used CRISPR/Cas9 genome editing to target Brg1 and Chd4, using an empty gRNA construct as 264 
control. We then analyzed chromatin accessibility by ATAC-Seq, hypothesizing that loss of Brg1 265 
and/or Chd4 would at least partially phenocopy the effect of UTX loss. We found 1150 sites with 266 
significantly decreased accessibility upon Brg1 editing and only 16 sites gained, suggesting that BRG1 267 
is mainly involved in the opening or maintenance of specific open chromatin loci (TableS20). We 268 
then overlapped these sites with regions that were differentially lost between Utx+/+ versus Utx-/- 269 
cells using the same culture conditions (2871 peaks, TableS21). We observed that 21% (244/1150) of 270 
regions closed in Brg1-edited cells overlapped with sites that closed upon Utx deletion (Fig.S8a-b). 271 
Of note, there was no further alteration of accessibility at these 244 sites when Brg1 was edited in 272 
Utx-/- cells (TableS22). This suggests a degree of functional redundancy between UTX and BRG1 loss 273 
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for chromatin accessibility. Performing motif analysis of these 244 sites, we again observed high 274 
enrichment for GATA motifs (Fig.S8a-b). Similar analysis for CHD4 demonstrated no significant 275 
overlap upon Utx loss (Fig.S8c, TableS23). These findings, along with our proteomic data suggest 276 
that UTX interacts with BRG1 to maintain chromatin accessibility at GATA bound regions.  277 
Utx loss allows chromatin accessibility to other transcription factors and facilitates the pioneering 278 
function of ETS factors during AML evolution. 279 
For sites newly accessible by ATAC-Seq following Utx loss, the converse was seen, with a correlation 280 
between these sites and increased H3K27Ac (766/1679 peaks, 45%)(Fig.S9a), H3K4Me1 (438/654 281 
peaks, 67%)(Fig.S9b) and gene expression close to the accessible sites (389/1517, 25%)(Fig.S9c, 282 
TableS24). Furthermore, motif analysis of newly accessible sites revealed enrichment for a number 283 
of transcription factors including ASCL1, E2A, EBF, PTF1a, TCF12, in addition to ETS factors (Fig.6b). 284 
Three transcription factors represented in the top five motifs (ASCL1, EBF, PTF1A) were not 285 
expressed in MONO-MAC6. Assessing the functional relevance of the two remaining expressed TFs, 286 
TCF3/E2A and TCF12/HEB, we utilized CRISPR/Cas9 editing in MONO-MAC6 and observed a 287 
significant reduction of cell growth upon knockout of either TCF3 or TCF12 (Fig.S9d) These data 288 
suggest that the transcriptional activity of TCF3 and TCF12 maintain AML growth in the absence of 289 
UTX. In assessing ETS sites, PU.1 binding sites gained in the absence of UTX only minimally 290 
overlapped with open chromatin at the pre-leukemic stage (758/8329 peaks, 9%). However, of 291 
significant interest, although the remaining 91% (7592 peaks, linked to 3450 genes) occurred in 292 
ATAC inaccessible chromatin in the PL stage and had no effect on gene expression following Utx loss, 293 
we documented that the expression of 691 of these linked genes (20%) was upregulated in the later 294 
transition to AML (Fig.6f-h, TableS25-S26). These data suggest that pioneering function of 295 
redistributed ETS TFs “primes” a later leukemogenic transcriptional program for upregulation during 296 
AML evolution. 297 
 298 
Discussion 299 
The mechanism of tumor suppression by UTX has been previously thought to be dependent on its 300 
demethylase catalytic function, a notion supported by data from T-ALL9,14. However, during the 301 
evolution of AML, we categorically demonstrate that the demethylase function of UTX is redundant 302 
for tumor suppression. Non-catalytic functions of UTX have previously been demonstrated in 303 
embryonic development22,29,30 and in mammary luminal lineage development31. UTX-catalytic activity 304 
was reported to upregulate expression of the master transcription factor PLZF and to modulate 305 
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super-enhancer accessibility in invariant natural killer T cells32. Additionally, UTX function was 306 
recently linked to enhancer activity and gene activation via coordination of COMPASS mediated 307 
H3K4monomethylation and CREBBP/p300 H3K27Ac33, as we also demonstrate here. However, no 308 
role for these functions in tumor suppression has been demonstrated until now. Furthermore, our 309 
study confirms and defines the molecular basis for the frequent co-occurrence of UTX and UTY 310 
mutation/loss6,7, identifying UTY as a tumor suppressor in its own right and highlighting non-catalytic 311 
functions of UTX/UTY as the dominant mediators of tumor suppression.  312 
Contrary to the prevailing perception that UTX is solely a transcriptional activator17, our study 313 
identifies that it also functions as a repressor. We demonstrate that its loss leads to significant 314 
alterations in chromatin accessibility, bidirectional alterations in H3K27Ac, a predominant loss of 315 
H3K4Me1 and coordinated changes in gene expression that impart pro-leukemic properties on 316 
HSPCs, alterations that are maintained during evolution to AML (Fig.S11). In particular, UTX loss 317 
upregulates a transcriptional program driven by the ETS family of pioneer transcription factors34,35,36. 318 
ETS factors are known to be oncogenic37,38, with overexpression of a single ETS factor, ERG, able to 319 
generate AML in mice39 and ERG expression levels being one of the strongest prognostic factors in 320 
human AML40. Novel binding events of the exemplar ETS factor PU.1, lead to an increase in 321 
chromatin accessibility, activation of enhancer modifications and, via its pioneering activity, gene 322 
activation occurring at later timepoints during leukemia evolution. Furthermore, loss of UTX also 323 
downregulates a program of GATA-driven genes through loss of chromatin accessibility and local 324 
H3K27 acetylation. GATA factors are also critical regulators of hematopoiesis and leukemia41, with 325 
germline and somatic loss-of-function mutations of GATA2 described in AML42,43. Taken together, our 326 
data demonstrate that UTX loss coordinates a “double-hit” mechanism reminiscent of genomic 327 
inversion that removes a critical enhancer to downregulate GATA2 expression and relocates it to 328 
drive oncogenic expression of the transcription factor EVI144. 329 
Our proteomic data also suggest that non-catalytic tumor suppressive functions operate through 330 
protein-protein interactions with tetratricopeptide repeats, the other major protein domain of 331 
UTX/UTY17. We could demonstrate protein interactions between endogenous UTX and the KMT2C/D-332 
containing COMPASS complex and the ATP-dependent chromatin remodeling factors, BRG1 and 333 
CHD4 in myeloid cells. The interaction between UTX and BRG1 was previously demonstrated in T 334 
lymphocytes45 and during cardiac development46. Loss of Utx led to a marked decrease in the 335 
deposition of the canonical early enhancer mark H3K4Me1. Notably, mutations of KMT2D are 336 
responsible for the majority (60-80%) of cases of Kabuki syndrome, with UTX mutations causing ~ 337 
10% of cases, thus highlighting the mechanistic links between the two proteins. Furthermore, we 338 
12 
 
could demonstrate co-occupancy of UTX, BRG1 and CHD427 at specific genomic loci associated with 339 
alterations in chromatin accessibility upon UTX loss (Fig. 6c-e). Furthermore, we could functionally 340 
demonstrate that BRG1 loss at least in part phenocopied the loss of chromatin accessibility seen 341 
upon Utx deletion. Recent studies demonstrate that H3K4Me1 is required for binding of the BRG1-342 
containing BAF complex to chromatin and enhances BAF chromatin-remodeling activity47. Our own 343 
data corroborate and extend this model further defining a role for UTX in linking H3K4Me1 344 
deposition with chromatin remodeling via BRG1. Taken all together, these mechanistic data 345 
demonstrate that loss of UTX leads to an upregulated activity of ETS transcription factors with both 346 
immediate and later pioneering effect to facilitate chromatin accessibility, and loss of coordination of 347 
COMPASS-mediated H3K4Me1 enhancer specification and BRG1-mediated chromatin accessibility. 348 
Together, these lead to alter patterns of gene expression to induce and maintain leukemia (Fig.S11).  349 
Our findings identify UTX as a complex transcriptional regulator capable of both activating and 350 
repressing transcription, through effects on pioneering transcription factors, enhancer function and 351 
chromatin accessibility, with obvious implications for its role in tumor suppression and other critical 352 
cellular processes. Finally, our framing of UTY as a bona fide tumor suppressor gene firmly 353 
establishes a pathogenic role for Y chromosome-specific genes in carcinogenesis, and throws new 354 
light on the role of Y chromosome loss in diverse cancer types and on the significance of age-related 355 
clonal hematopoiesis associated with “loss-of-Y” in otherwise healthy men48-50. 356 
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Figure Legends 516 
Figure 1. Utx-/- mice develop acute myeloid leukaemia  517 
(a) Structure of the Utx conditional allele. (b) qRT-PCR for exons 2-3 of Utx confirms Utx loss in Utx-/- 518 
HSPCs. The mean ± s.e.m is shown; n= number of mice per genotype; P by two-sided t-test, t=10.93, 519 
df=63. (c) Immunoblot showing loss of UTX protein in Utx-/- BM. Results of one representative 520 
experiment are shown (n=3 experiments). Uncropped images are shown in Fig.S12 (d) Kaplan-Meier 521 
survival curves for female Utx-/- (median 483 days), Utx+/- (median 661 days) and Utx+/+(median 522 
survival not reached) mice;  n= number of mice per genotype; P by Log-rank (Mantel-Cox) test, df=2. 523 
(e) Spleen weights of Utx-/-, Utx+/- and Utx+/+mice; mean ± s.e.m. is shown; n= number of mice per 524 
genotype; P value was determined by one-way ANOVA with Bonferroni correction, t=2.554, df=55. 525 
(f) Characteristic Mac1/Gr1 fluorescence activated cell sorting (FACS) analysis of BM and spleen cells 526 
from one diseased Utx-/- mice (similar result was observed in n=12). (g) Histopathological diagnoses 527 
of moribund mice of indicated genotypes. The number of mice with a cancer diagnosis and the total 528 
analysed is indicated for each genotype. B-ALL: B-cell ALL; MPN: myeloproliferative neoplasm; other: 529 
non-hematological tumors; other (n/s): non-specified. (h) Characteristic histology from one mouse 530 
with AML is shown (similar results were observed in n=20 mice). Sp=spleen, Li=liver. (i) Kaplan-Meier 531 
survival curves of mice transplanted with Utx-/- leukemias: AL: acute leukemia unclassified (n=5), T-532 
ALL: T cell acute lymphoblastic leukemia (n=5), and two AML (n=9). 533 
Figure 2. Utx loss expands hematopoietic stem/progenitor cells and imparts a myeloid bias, 534 
characteristics rescued by Uty 535 
(a) Pre-leukaemic spleens, (b) spleen weights (t=10.93, df=63) (c) Lin- cell (HSPC)(t=6.908, df=9) and 536 
(d) LT-HSC (t=3.712, df=9) and ST-HSC frequency in BM from Utx+/+ and Utx-/- (t=4.049, df=9) (e) 537 
Representative FACS-profiles of CMP, GMP and MEP (similar to other 5 mice). (f) Quantitation of LK 538 
(Lin-Sca1-c-Kit+)(t=2.927, df=14), CMP(t=3.518, df=14), GMP (t=3.608, df=14), and MEP (t=6.181, 539 
df=15) from Utx+/+ and Utx-/- mice. (g) CLP frequency in BM from Utx+/+ and Utx-/- mice (t=3.534, df=5). 540 
(h) Serial re-plating of BM-derived colonies from Utx+/+, Utx+/-, Utx-/- (for Utx+/+ vs Utx-/- in plating: 1, 541 
t=7.164; df=19; 2, t=3.991, df=19; 4, t=5.489, df=11; 5, t=3.292, df=11) (i) Schematic summary of 542 
progenitor differentiation in Utx-/-. Green arrows= preferential differentiation; red lines= 543 
differentiation block. (j) Kaplan-Meier survival curves of Utx-/Y and Utx+/Y compared to Utx-/-; P=ns 544 
between Utx-/Y and Utx+/Y by Log-rank (Mantel-Cox) test, df=1 (k) Histopathological diagnoses of 545 
moribund mice. Numbers of mice with a cancer diagnosis and total analysed indicated for each 546 
genotype. (l) Schematic summary of progenitor differentiation in Utx-/Y. (m) serial re-plating and (n) 547 
proliferation of Cas9-expressing HSPCs upon Uty editing; for m and n, cells were isolated from n=3 548 
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mice per genotype; the mean ± s.e.m is shown; P by one-way ANOVA with Bonferroni correction (P 549 
shown for Cas9, Utx-/Y gRNA-Uty versus Cas9, Utx+/Y gRNA-Uty, in m for plating: 3 (t=4.313, df=8), 550 
4(t=5.522,df=8); in n for culture days: 4 (t=3.176, df=8); 6, (t=3.994, df=8); 7, (t=4.537, df=7); . In c, d, 551 
f, g, the mean ± s.e.m is shown; n= number of mice; P by two-sided t-test. In b and h, mean ± s.e.m is 552 
shown; P by one-way ANOVA with Bonferroni correction. 553 
Figure 3. H3K27 demethylase activity is not required for tumor suppression by UTX  554 
(a) Experimental approach for study of UTX-mutant-MONO-MAC6 after expression of FLAG, UTX, 555 
UTY and UTX-MT2. (b) Compared to FLAG; UTX, UTY and UTX-MT2 reduced MONO-MAC6 556 
proliferation; the mean ± s.e.m is shown; n=independent cultures;  P by one-way ANOVA with 557 
Bonferroni correction. Day3 (compared to FLAG): UTX (t=5,633; df=8), UTY (t=3,95; df=8); day4: UTX 558 
(t=6.866; df=8), UTY(t=5.444; df=8); day5: UTX(t=4.976; df=8), UTY(t=4.216; df=8) (c) Colony 559 
formation in semisolid media, upper panel - similar result observed in n=3 cultures; lower panel-560 
colony quantification; the mean ± s.e.m is shown; n=3 independent cultures;  P by one-way ANOVA 561 
with Bonferroni correction; compared to FLAG: for UTX t=10.19, df=8; UTX-MT2 t=10.36, df=8; UTY 562 
t=7.955; df=8 (d-e) in vivo growth after transplantation into immunocompromised mice. Cells were 563 
also transduced with luciferase-expressing vector and mice imaged on days 6, 20 and 27 after 564 
transplant. The mean ± s.e.m is shown; P by one-way ANOVA with Bonferroni correction: ** P (FLAG 565 
vs UTX)=0.0131, t=3.317, df=16; P (FLAG vs UTY)= 0.0242, t=3.025, df=16; P(FLAG vs UTX-566 
MT2)=0.0095, t=3.469, df=16; * P(FLAG vs UTX) =0.0013, t=4.408, df=16; P(FLAG vs UTY) = 0.1284, 567 
t=2.2, df=16; for P(FLAG vs UTX-MT2)=0.0010, t=4.524; df=16. (f) Kaplan-Meier survival curves of 568 
transplanted mice; n=number of mice, P by Log-rank (Mantel-Cox) test reported versus FLAG, df=1  569 
(g) Immunoblot analysis of UTX in AML lines; similar result observed in n=3 experiments. Uncropped 570 
images are shown in Fig.S12 (h) qRT-PCR for UTY in AML and (i) in non-hematopoietic cancer cell 571 
lines with UTX mutations, for h and i, the mean ± s.e.m is shown; n=3 independent cell cultures.  572 
Figure 4. Utx loss drives both up and down regulation of gene expression primarily through effects 573 
on H3K27 acetylation   574 
(a) Pre-leukaemic gene expression changes in HSPCs from Utx-/- female (n=2 mice) and Utx-/Y male 575 
(n=2 mice) compared to sex-matched wild-type controls (n=2 mice); genes with adj. P<0.05 are 576 
shown. Subtraction of genes differentially expressed in males from those in females defines a 577 
differential transcriptional program of interest; log2FC (-0.5>log2FC>0.5)(b) Volcano plot of fold-578 
change (-0.5>log2FC>0.5) and adj. P <0.05 (only transcripts with P values between 0.05 and 1e-38 are 579 
shown) for genes differentially expressed in the pre-leukaemic and AML setting. In a and b the P was 580 
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generated using a negative binominal generalized linear model (DESeq2). (c) Overlap between 581 
differentially expressed genes in Utx-/- pre-leukaemic HSPCs (n=2 mice) and AMLs (n=3 mice), each 582 
compared to Utx+/+ HSPC (n=2 mice); P by hypergeometric test. (d) Distribution of UTX ChIP-Seq 583 
peaks in annotated regions of the genome. (e) Highly significant enrichment of UTX-bound genes 584 
amongst those differentially expressed in pre-leukaemic Utx-/- HSPCs; P by hypergeometric test. (f) 585 
H3K27Me3 (g) H3K27Ac and (h) H3K4Me1 density plots (left) and average read counts (right) across 586 
all (global changes) or differentially modified regions (local changes). H3K27Me3 signal density show 587 
that only 302 genomic regions were differential modified, in contrast to similar plots for H3K27Ac 588 
reveals 5120 and for H3K4Me1 4552 differential modifications in Utx-/- vs Utx+/+ HSPC. Arrows show 589 
each replicate (mouse) per genotype. FDR was calculated using DiffBind tool; n=2 mice per 590 
genotype.  Plots are peak centered, scaled and ± 1kb for each locus. Shaded region in the line graphs 591 
in f-h indicate the standard errors. 592 
Figure 5. Utx loss activates an oncogenic ETS transcriptional program while suppressing a GATA 593 
program 594 
Volcano plots of differentially expressed genes in (a) pre-leukaemic (n=2 mice) and (b) AML Utx-/- 595 
(n=3 mice) compared to wild-type controls (n=2 mice) reveal overexpression of multiple ETS factors 596 
(red dots). Fold-change (-0.5>log2FC>0.5) and adj. P <0.05 (only transcripts with P values between 597 
0.05 and 1e-38 are shown in the graph); P was generated using DESeq2. (c) GSEA plot shows 598 
significant overlap with a known ETS oncogenic program driven by the EWSR1-FLI1 fusion. (d) Motif 599 
analysis of UTX ChIP-Seq peaks that overlap with overexpressed genes; number indicates motif rank 600 
(e) MONO-MAC6 proliferation upon editing of indicated gene. BFP-positive fraction was compared 601 
with the non-transduced population and normalized to day 4 (d4) for each gRNA. The mean ± s.d. is 602 
shown; n=independent cell cultures; P by one-way ANOVA with Bonferroni correction; P shown for 603 
day19 compared to control gRNA (EMPTY). Compare to EMPTY for: ELF4 t=32.32; ETV6 t=10.03; FLI1 604 
t=41.1; ETS1 t=15.85; PU.1 t=33.56; ELF1 t=3.967; ERG=12.35 and df=16. (f) GSEA plot showing 605 
enrichment of genes differentially expressed in Utx-/- HSPCs with a published dataset of GATA2 606 
targets. (g) Motif analysis of 3442 downregulated H3K27Ac peaks (FDR<1%, FC<-1.5) identified in 607 
Utx-/- HSPCs, number indicates motif rank. (h) Selected proteins identified by mass spectrometry 608 
after immunoprecipitation of endogenous UTX from murine myeloid cells (416B) (n=2 independent 609 
cell cultures). Motif and statistical analysis in d and g was determined by HOMER software (see 610 
Methods and TableS30). 611 
Figure 6. UTX interacts with chromatin modifiers to maintain chromatin accessibility  612 
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(a) Motif analysis of ATAC-Seq closed and (b) open peaks reveals dramatic enrichment for GATA 613 
motifs in the former and ETS, amongst other motifs, in the latter; number indicates motif rank. Motif 614 
and statistical analysis was determined by HOMER software (TableS30) (c) Genomic snapshot of 615 
GATA2, UTX, ATAC-Seq and H3K27Ac ChIP-Seq in Utx+/+ and Utx-/- HSPCs at the Ets2 and (d) Steap3 616 
loci. Note co-localization of GATA2 binding with dynamically closed chromatin and loss of H3K27Ac 617 
following UTX loss, without evidence for GATA2-UTX co-binding. By contrast, binding of the 618 
chromatin remodelers BRG1 and CHD4 directly co-localize with UTX binding (lower two tracks). At 619 
the Ets2 locus, newly accessible chromatin is also seen following UTX loss, again at regions not 620 
directly bound by UTX or chromatin remodelers. (e) Density plots of UTX, BRG1 and CHD4 ChIP-Seq 621 
on UTX-bound genomic loci; Venn diagram shows overlap between all UTX, BRG1 and CHD4 ChIP-622 
Seq peaks; P by Fisher’s exact test for ChIP-Seq: UTX vs BRG1/CHD4 (f) Schematic representation of 623 
PU.1 occupancy occurring mostly on closed chromatin. (g) Overlap of genes associated with 624 
enhanced PU.1 binding (in Utx-/-) on closed chromatin with gene expression changes from pre-625 
leukemia (PL) to AML. For PU.1 ChIP-Seq n=3 mice; ATAC-Seq n=3 mice; PL RNA-Seq n=2 mice; AML 626 
RNA-Seq n=3 mice. P by hypergeometric test. (h) Genomic snapshot demonstrating enhanced PU.1 627 
occupancy in Utx-/- HSPCs that occurs on closed chromatin at the Rab11a locus and correlation with 628 
PL and AML RNA-Seq. Note Rab11a expression increases only upon progression to AML. 629 
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Methods 630 
Mice 631 
The In vivo experiments were performed under the project licence PPL 80/2564 issued by the United 632 
Kingdom Home Office, in accordance with the Animal Scientific Procedures Act 1986. The Utx mouse 633 
model, C57Bl6, was developed at the Sanger Institute. Utxf/f mice were crossed with Flpe mice and 634 
then with Mx1-Cre mice. Cre expression was induced by intraperitoneal injection of 5-6 -week -old 635 
mice with pIpC (Sigma #P1530, 400 µg/mouse; 5 doses over a period of 10 days). All pre-leukaemic 636 
experiments were performed 4-6 weeks post pIpC injection. Cas9-expressing mice were reported 637 
previously28. 638 
Cell lines 639 
293FT (Invitrogen) were cultured in DMEM (Invitrogen), supplemented with 10% FBS. 416B cells 640 
were cultured in RPMI1640 (Invitrogen), 10% FBS. SN12C, KU-19-19, KYSE-180 and HCC2998 were 641 
cultured in RPMI (Invitrogen) supplemented with 10% FBS (Invitrogen); J82, UM-UC-3 and FADU 642 
were cultured in EMEM (Invitrogen), 10% FBS; CAL-27 and VM-CUB-1 were cultured in DMEM 643 
(Invitrogen), 10% FBS. SW684 was cultured in L15, 10% FBS. LB996-RCC was cultured in IMDM 644 
(Invitrogen), 10% FBS (Invitrogen). D-423MG was cultured in Gibco Zinc Option (Invitrogen), 10% 645 
FBS; KYSE-270 in RPMI & Ham’s F12, 2% FBS. Each of the media was supplemented with 1% 646 
penicillin/streptomycin/glutamine (PSG, Invitrogen). AML cell lines: MV4-11, MONO-MAC6 and THP1 647 
were cultured in RPMI1640 (Invitrogen) supplemented with 10% FBS and 1% PSG. OCI-AML2 and 648 
OCI-AML3 were cultured in alpha-MEM (Lonza), 20% FBS and 1% PSG.  All cancer cell lines were 649 
obtained from the Sanger Institute Cancer Cell Collection. 650 
cDNA synthesis, PCR and qRT-PCR 651 
cDNA synthesis was performed using a qScript cDNA SuperMix (Quanta Biosciences) according to the 652 
manufacturer’s instructions. PCR was performed with REDTaq ReadyMix PCR Reaction Mix (Sigma) 653 
according to the manufacturer’s instructions. qRT-PCR was performed using TaqMan Fast Universal 654 
PCR Master Mix (Thermo Fisher Scientific) and the Universal Probe Library system (Roche). The TBP 655 
housekeeping gene was used for data normalization. qRT-PCR primer sequences are presented in 656 
(TableS27).  657 
Protein extraction, Immunoblot, co-immunoprecipitation 658 
The cells were lysed in whole cell lysis buffer (50 mM Tris-HCl pH=8, 150 mM NaCl, 0.1% NP-40, 1 659 
mM EDTA), supplemented with 1 mM DTT, protease inhibitors (Sigma), and phosphatase inhibitors 660 
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(Sigma). Protein concentrations were assessed by Bradford assay (Bio-Rad) and an equal amount of 661 
protein was loaded per track. Prior to loading, the samples were supplemented with SDS-PAGE 662 
sample buffer and DTT was added to each sample. 10-40 µg of protein was separated on a 10% SDS-663 
PAGE gel, and blotted onto polyvinylidene difluoride membranes (Millipore). The following primary 664 
antibodies were used: anti-UTX (Bethyl, A302-374A), anti-UTX (GeneTex, GTX121246) and anti-IgG 665 
(Santa Cruz Biotechnology, sc-2027) and anti-α-tubulin (Sigma, T6074) or anti-ACTIN (Santa Cruz 666 
Biotechnology, sc-1616) a loading control. The secondary antibodies used in the study were as 667 
follows: HRP-linked donkey anti-rabbit (GE Healthcare UK); ECL HRP-linked anti-mouse (Santa Cruz 668 
Biotechnology, sc-2005). Visualization was performed via LumiGLO Chemiluminescent Substrate 669 
(KPL, 54-61-00). Co-immunoprecipitation (co-IP) was performed in the extracts isolated with cell lysis 670 
buffer (as above). 2-6 ug of antibody were bound to 20ul of Dynabeads Protein G (Thermo Fisher 671 
Scientific) beads and incubated with 500-1000 µg of freshly extracted protein for 1,5h at 4°C with 672 
rotation. IP was washed 4 times with IP wash buffer (10 mM Tris-HCl pH=8, 150 mM NaCl, 0.1% NP-673 
40, 1 mM EDTA), supplemented with protease inhibitor (Sigma). IP samples with beads were then 674 
resuspended in 1x NuPAGE LDS Sample Buffer (Thermo Fisher Scientific), supplemented with 675 
NuPAGE Sample Reducing Agent (Thermo Fisher Scientific). The following antibodies were used for 676 
IP; anti-CHD4 (Abcam, ab72418), anti-BRG1 (Santa Cruz Biotechnology, sc-10768) anti-UTX (Bethyl, 677 
A302-374A) and IgG (Santa Cruz Biotechnology, sc-2027). 678 
Histological analysis of mouse tissue 679 
The tissues were fixed in 10% formaldehyde and subsequently paraffin embedded. Bones were 680 
decalcified using 0.38 M EDTA pH=7. Tissue sections (4 µm) were stained with Hematoxylin and 681 
Eosin (Thermo Fisher Scientific). Histology assessment was performed using the Bethesda criteria for 682 
mouse hematological tumors51,52.   683 
 684 
Blood count analysis 685 
Blood count measurement was performed on a VetabC analyzer (Horiba ABX). 686 
Isolation of mouse hematopoietic progenitors 687 
Freshly isolated bone marrow was suspended in erythrocyte lysis solution (BD PharmLyse, BD 688 
Bioscience), followed by magnetic bead selection of Lin- cells, using the Lineage Cell Depletion Kit 689 
(Miltenyi Biotec, cat. no. 130-090-858) according to the manufacturer’s instructions. c-KIT+ 690 
progenitors were selected with mouse CD117 MicroBeads, (Miltenyi Biotec, #130-091-224) 691 
according to the manufacturer’s instructions. 692 
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Culture of mouse hematopoietic progenitors 693 
Primary mouse cells were cultured in X-VIVO 20 media (Lonza) supplemented with 5% serum (Stem 694 
Cell Technologies),  10ng/ml IL3 (Peprotech), 10ng/ml IL6 (Peprotech) 50ng ml/ml of SCF (Peprotech) 695 
and 1% penicillin-streptomycin-glutamine (Gibco). 696 
FACS analysis 697 
Bone marrow cells were incubated in erythrocyte lysis buffer: 0.85% NH4Cl (Sigma) and blocked with 698 
anti-mouse CD16/32 (BD Pharmigen, #553142) and 10% mouse serum (Sigma M5905) for LSK and 699 
CLP staining or 10% mouse serum alone for LK staining. LSK, MPP, LMPP, LT/ST-HSC FACS staining 700 
was performed using the following antibody against: CD4 (Biolegend, #100514), CD5 (Biolegend, 701 
#100610), CD8a (Biolegend, # 100710), CD11b (Biolegend, #101210), B220 (Biolegend, #103210), 702 
TER-119 (Biolegend, #116210), GR-1 (Biolegend, #108410) as well as SCA-1 (Biolegend, #122520), 703 
CD117 (eBioscience, # 47-1171); CD48  (Biolegend, #103411), CD150 (Biolegend, #115913), CD34 (BD 704 
Pharmigen, #553733), FLT3 (eBioscienc, #12-1351).  GMP, MEP, CMP staining was performed with 705 
the following biotin-conjugated lineage markers: MAC1, GR1, CD3, B220, TER119 (BD Pharmigen, 706 
#559971), and IL7Ra (Biolegend, #121103), Streptavidin (Biolegend, #405206) alongside with CD34 707 
(BD Pharmigen, #553733), CD16/32 (BD Pharmigen, #553145), c-KIT (BioLegend, #105812), SCA-1 708 
(Biolegend, #122520). For the detection of the CLP population cells were stained with the Flt3 709 
(eBioscienc, #12-1351), IL7Ra (BioLegend, #135008), lineage-biotin conjugated markers: MAC1, GR1, 710 
CD3, B220, TER119 (BD Pharmigen, #559971), as well as NK (LSBio, LS-C62548) c-KIT (BioLegend, 711 
#105812) and SCA-1 (Biolegend, #122520). Differentiated bone marrow, spleen and peripheral blood 712 
cells were stained with CD45 (BD Pharmigen, #563891), CD11b (BD Pharmigen, #557657), B220 713 
(Biolegend, #103210), GR1 (BD Pharmigen, #560603), c-KIT (BioLegend, #105812), TER119 (BD 714 
Pharmigen, #557915) and CD3e (eBioscience, #12-0031-82). LT-HSC: long term hematopoietic stem 715 
cells were defined as: Lin-, c-KIT+, SCA1+, FLT3-, CD48-, CD150+, CD34-; ST-HSC: short term HSC as Lin-, 716 
c-KIT+, SCA1+, FLT3-, CD48-, CD150+, CD34+; MPP: multipotent progenitors (Lin-, c-KIT+, SCA1+, FLT3+); 717 
LMPP: lymphoid primed multipotent progenitors (Lin-, c-KIT+, SCA1+, FLT3hi), CLP: common lymphoid 718 
progenitors (Lin-, FLT3hi, IL7Ra+, c-KITlo, SCA-1lo), GMP: granulocyte-monocyte progenitors (Lin-, IL7Ra-719 
, c-KIT+, SCA1-, CD34+, CD16/32+); CMP: common myeloid progenitors (Lin-, IL7Ra-, c-KIT+, SCA1-, 720 
CD34+, CD16/32-), MEP: megakaryocyte-erythroid progenitors (Lin-, IL7Ra-, c-KIT+, SCA1-, CD34-, 721 
CD16/32-). Flow cytometry analysis was performed using the LSRFortessa instrument (BD) and 722 
analysed using FlowJo software. 723 
Serial re-plating assay 724 
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For re-plating assays 50,000 bone marrow cells were plated in two wells of 6-well-plate of M3434 725 
methylcellulose (Stem Cell Technologies). The colonies were counted 7 days later and further 30,000 726 
cells re-seeded and re-counted after a week until no colonies were observed.  727 
Proliferation assay 728 
104 cells /well were plated onto 96-well plates and assayed daily for growth using CellTiter 96 729 
AQueous Non-Radioactive Cell Proliferation Assay (Promega) according to manufactures’ 730 
instructions. 731 
Plasmids, cloning 732 
FLAG-tagged versions of UTX, UTY, UTX-MT2 plasmids were purchased from Addgene (pCS2-UTX-F 733 
#24168, pCS2-UTY-F #17439 and pCS2-UTX-F-MT2 #40619). The lentiviral UTX, UTY, UTX-MT2 and 734 
FLAG expression vectors were constructed in pKLV-puro as follows. Firstly, the lentiviral backbone 735 
vector, pKLV-U6(Flip)gRNA(BbsI)-PGKpuro2ABFP53 was digested with BbsI and KpnI to remove the 736 
U6gRNA(BbsI)-PGKpuro2ABFP cassette. Gibson cloning (NEB) was performed to clone the PCR 737 
products for EF1α promoter, UTX/UTY/UTX-MT2/FLAG cDNA and puromycin (Puro) resistance gene 738 
with the primers in (TableS28). EF1α promoter was PCR amplified from pLVX-EF1α-IRES-ZsGreen1 739 
construct (Clontech, 631982). Puro resistance gene was amplified from pKLV-U6(Flip)gRNA(BbsI)-740 
PGKpuro2ABFP construct. Gibson cloning was performed according to manufacturer’s specification. 741 
Firefly luciferase expressing plasmid (EF1α-GFP-T2A-Luciferase) was obtained from System 742 
Biosciences (BLIV503-MC-1-SBI). AML-ETO9a plasmid was published before54. For CRISPR/Cas9 743 
experiments gRNA were cloned into BbsI digested pKLV2-U6gRNA(BbsI)PGKpuro2ABFP backbone28. 744 
Sequences of gRNA used in the study are provided in TableS.29. 745 
Lentiviral vector production and transduction 746 
Lentiviruses were produced in HEK293 cells using ViraPower Lentiviral Expression System 747 
(Invitrogen) according to manufacturer's instructions. Viral supernatant was concentrated by 748 
centrifugation at 6000g, 16h, at 4 °C.  The cells were transduced by spinoculation (60 min, 800 g, 32 749 
°C) in culture medium supplemented with 4µg/ml of polybrene (Millipore) and further incubated 750 
overnight at 37 °C. The following day, the transduced cells underwent selection on puromycin, 751 
(1.5ug/ml, Sigma) for three days. 752 
Transplant; in vivo imaging and quantification  753 
MONO-MAC6 cell line was transduced with lentiviral vectors expressing UTX, UTY, UTX-MT2 or FLAG 754 
control, puromycin-selected for 4 days. 0.8x106 cells were transplanted via i.v. tail injection into 755 
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immunocompromised recipient mouse (Il2rg-/-; Rag2-/-). Five mice were injected per group. For 756 
bioluminescence examination mice were injected with D-luciferin (BioVision; 3mg/20g, i.p.) and 757 
subsequently anesthetized with isoflurane. Bioluminescence was quantified with an In Vivo Imaging 758 
System IVIS Lumina II (Caliper), with Living Image version 4.3.1 software (PerkinElmer) according to 759 
manufactures’ instructions.  760 
AML-ETO9a transplants: c-KIT positive cells from the BM of Utx+/+ and Utx-/- mice and transduced 761 
them with lentiviral vectors expressing the AML-ETO9a fusion. 1x106 cells were subsequently 762 
transplanted into lethally irradiated syngeneic recipient mice (n=9-10/group). 763 
Secondary transplant of mouse Utx-/- leukemias: 1x106 splenocytes were injected into sublethally 764 
irradiated recipient mice: acute leukaemia unclassified (n=5 mice), T-ALL (n=5 mice), and two AML 765 
(n=9 mice).  766 
RNA extraction, RNA-Seq analysis 767 
RNA was extracted from HSPC/Lin- BM cells using Arcturus Picopure RNA Isolation Kit (Thermo Fisher 768 
Scientific) according to the manufacturer’s instructions. RNA from murine primary AML samples was 769 
extracted with Trizol reagent (Thermo Fisher Scientific). RNA from human cell lines was extracted 770 
with RNeasy kit (Qiagen) according to the manufacturer’s instructions. RNA-Seq library was 771 
generated using TruSeq Stranded mRNA Sample Prep Kit (Illumina) and sequenced on Illumina 772 
HiSeq2000 v4 chemistry, 75-bp paired-end sequencing. RNA-Seq reads for each library were mapped 773 
using TopHat version 2.0.13 against the mouse genome build GRCm38.68, downloaded via Ensembl 774 
BioMart data mining tool. HiSeq libraries were aligned with the following options: "--keep-fasta-775 
order --no-sort-bam -r 100 -p 12 --library-type fr-firststrand --no-coverage-search --microexon-776 
search --transcriptome-index=GRCm38.known" where GRCm38.known is a transcriptome index file 777 
in GTF format prepared beforehand by an initial single TopHat run without input reads. Raw counts 778 
for each gene in the Genome Reference Consortium genome assembly (GRCm38.68) were obtained 779 
with Bioconductor package GenomicAlignments version 1.2.2 with mode="Union". Differential 780 
expression analysis was carried out with these counts using Bioconductor package DESeq2 version 781 
1.6.3 with BH independent filtering method with an FDR of 1%; both packages were used according 782 
to their vignettes. Fold changes in expression were also calculated by DESeq2 after correcting for 783 
differences in library sizes. 784 
ChIP-Seq, ChIP-qPCR 785 
ChIP-Seq experiments were performed on primary HSPC cells. For histone ChIP-Seq cells were fixed 786 
in 1% formaldehyde (FA, Thermo Fisher Scientific, #28906) for 5 mins at room temperature. The 787 
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reaction was stopped by the addition of glycine (0.125M, Sigma) and the cells were washed in ice-788 
cold PBS. The cells were then processed with iDeal ChIP-Seq kit for Histones (Diagenode) with 789 
following antibody anti: H3K4Me1 (Diagenode, #pAb-194-050), H3K27Me3 (Abcam, #Ab6002), 790 
H3K27Ac (Diagenode, #pAb-196-050).  For PU.1 ChIP-Seq cell were fixed with 1% FA for 10 mins at 791 
room temperature and processed with iDeal ChIP-Seq kit for Transcription Factors (Diagenode) 792 
according to manufacturer's instructions, with anti-PU.1 antibody (Santa Cruz Biotechnology, sc-793 
352x).  ChIP-Seq for UTX was performed in HSPCs. The cells were crosslinked with 2 mM 794 
Disuccinimidyl Glutarate (DSG, Sigma) for 30 mins at RT followed by the second crosslinking with 1% 795 
FA for 30 mins at 4°C. The cells were then processed with iDeal ChIP-seq kit for Transcription Factors, 796 
with anti-UTX antibody (Bethyl, A302-374A). Primer sequences used for ChIP-qPCR are listed in 797 
(TableS27).  798 
For BRG1, CHD4, UTX ChIP-qPCR 416B cells were crosslinked with 2 mM Disuccinimidyl Glutarate 799 
(DSG, Sigma) for 30 mins at RT followed by the second crosslinking with 1% FA for 10 mins at RT. 800 
Crosslinking was stopped by addition of 125 mM glycine. Cells were resuspended in ChIP Lysis Buffer 801 
(1%SDS, 10mM EDTA, 50mM Tris-HCl pH=8, protease inhibitors) and sonicated in Bioruptor Pico 802 
(Diagenode) for 10 cycles. Sonicated chromatin was diluted 1:10 in modified RIPA buffer (1% Triton; 803 
0.1%  deoxycholate; 90mM NaCl; 10mM Tris-HCl pH8; EDTA free protease inhibitors) and incubated 804 
overnight with 3ug of anti-BRG1 (Santa Cruz Biotechnology, sc-10768X) or anti-CHD4 (Abcam, 805 
ab72418) antibody. Next protein A/G (50% A 50% G) Dynabeads (Invitrogen) were added to the 806 
chromatin and incubated 2h at 4°C followed by magnetic separation. Beads were subsequently 807 
washed twice with mixed micelle buffer (150 mM NaCl, 0.2% SDS, 20 mM Tris-Cl pH 8.0, 5 mM EDTA, 808 
5.2% sucrose, 1% Triton X-100); high salt buffer (250 mM NaCl, 5 mM Tris-Cl pH 8.0, 0.5 mM EDTA, 809 
0.05% sodium deoxycholate, 25 mM HEPES pH 8.0, 0.5% Triton X-100) and LiCl buffer (250 mM LiCl, 810 
10 mM Tris-Cl pH 8.0, 10 mM EDTA, 0.5% NP40-Nonidet, 0.5% Sodium Deoxycholate) and once with 811 
elution buffer (1%SDS; 100mM NaHCO3). Beads were then resuspended in elution buffer 812 
supplemented with DNAse free RNAse (Roche, #11119915001). Cross-linking was reverted by the 813 
incubation at 37˚C for 30min followed by the incubation at 65˚C overnight. DNA was purified using 814 
the Chip-DNA purification kit (Zymo).  815 
Chip-Seq, motif analysis and GSEA, data visualization 816 
Adapter sequences were trimmed for all paired end reads and mapped against mm10 reference 817 
genome using Bowtie255. All the samples were processed independently and uniquely mapped reads 818 
were retained. Peaks were called using SICER56 with W200 and G600 for broad peaks and W200 and 819 
G200 for narrow peaks. Peak calling were perform for each of the replicate individually. Motif 820 
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analysis and peaks were annotated using HOMER35. Detail output of HOMER Motif analysis is 821 
included in TableS30. Peaks in intergenic regions were assigned to genes if they were within the 822 
100kb window from the TSS. Differential binding analysis was performed using DiffBind57 by groping 823 
replicates together. Overlapping peak analysis was performed using intersected from bedtools58. The 824 
statistical analysis of the overlapping peaks was performed using fisher’s exact test from bedtools. 825 
Each of the ChIP-Seq experiments, with exception of the PU.1 ChIP-Seq, was performed in biological 826 
duplicates. PU.1 ChIP-Seq was performed in biological triplicates. Gene set enrichment analysis tools 827 
were obtained from The Broad Institute59. ChIP-Seq; RNA-Seq and ATAC-Seq data were visualized in 828 
UCSC Genome Browser60. Venn diagrams were performed using BioVenn web application61. All 829 
graphs were perform in GraphPad Prism unless specify otherwise.  830 
Promoter-enhancer interaction analysis 831 
Promoter-associated interaction matrix of multipotent hematopoietic progenitor cell line 7 (HPC-7) 832 
was generated in a previous study using Promoter Capture Hi-C (PCHi-C) method and data were 833 
analysed with CHiCAGO package23. Genome coordinates from the interaction matrix were converted 834 
from mm9 to mm10. In total, 54,339 regions that form significant interactions (CHiCAGO score ≥ 5) 835 
with promoter baits were defined as promoter-interacting regions (PIRs). Differential H3K27Ac peaks 836 
in Utx-/- versus Utx+/+ were grouped as increased (UP) or decreased (DOWN) peaks and intersected 837 
with PIRs using bedtools. Interactions at specific gene loci were visualized in WashU Epigenome 838 
Browser. 839 
ATAC 840 
The ATAC-Seq method was used based on the established protocol62 with modifications63. Briefly, 841 
200,000 cells were washed in 0.3 mL of ice-cold Dulbecco’s phosphate buffered saline without 842 
calcium and magnesium. This was followed by centrifugation at 300g for 3 minutes before 843 
resuspending in 400 µL of freshly-made ice-cold sucrose buffer (10 mM Tris-Cl pH 7.5, 3 mM CaCl2, 2 844 
mM MgCl2 and 0.32 M sucrose) and incubated on ice for 12 minutes. 10% Triton X-100 was added to 845 
a final concentration of 0.5 % and the cells were vortexed briefly before incubating on ice for a 846 
further 6 minutes to access nuclei. The nuclei were briefly vortexed again before another 847 
centrifugation at 300g for 3 minutes at 4 °C. The sucrose/triton lysis buffer was removed before 848 
immediately resuspending the nuclei pellet in 50 µL of Nextera tagmentation master mix, comprising 849 
25 µL 2x Tagment DNA buffer, 20 µL nuclease-free water and 5 µL Tagment DNA Enzyme 1 (Illumina 850 
FC-121-1030). The tagmentation reaction mixture was immediately transferred to a 1.5 mL low-bind 851 
microfuge tube and incubated at 37 °C for 30 minutes. The tagmentation reaction was stopped by 852 
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the addition of 500 µL Buffer PB (Qiagen). The tagmented chromatin was purified using the MinElute 853 
PCR purification kit (Qiagen 28004), according to the manufacturer’s instructions, eluting in 10 µL of 854 
buffer EB (Qiagen). 10 µL of the tagmented chromatin was mixed with 2.5 µL Nextera PCR primer 855 
cocktail and 7.5 µL Nextera PCR mastermix (Illumina FC-121-1030) in a 0.2 mL low-bind PCR tube. 2.5 856 
µL of an i5 primer and 2.5 µL of an i7 primer (Illumina FC-121-1011) were added per PCR, totaling 25 857 
µL.  PCR amplification was performed as follows: 72 °C for 3 minutes and 98 °C for 30 seconds, 858 
followed by 12 cycles of 98 °C for 10 seconds, 63 °C for 30 seconds and 72 °C for 3 minutes. Libraries 859 
were size-selected on a 1 % agarose TAE gel, collecting library fragments from 120 bp to 1 kb. Gel 860 
slices were extracted with the MinElute Gel Extraction kit (Qiagen 28604), eluting in 20 µL of Elution 861 
Buffer.  Samples were further purified using Agencourt AMPure XP magnetic beads (Beckman 862 
Coulter A63880) at a ratio of 1.2 AMPure beads :1 PCR sample (v/v), according the manufacturer’s 863 
instructions, eluting in 20 µL of Buffer EB (Qiagen). Before sequencing, each ATAC-seq library was 864 
assessed on an Agilent 2100 Bioanalyzer using a High Sensitivity DNA chip (Agilent Technologies 865 
5067-4626).  866 
 867 
ATAC Sequencing analysis 868 
Similar to ChIP-Seq analyses all the adapter sequenced of ATAC-Seq paired end reads were trimmed 869 
and mapped against mm10 reference genome using Bowtie2. All the samples were processed 870 
independently and uniquely mapped reads were retained. Peaks were called with MACS264 with –871 
nomodel and –nolambda parameters. Peak calling was performed individually for each of the 872 
replicate. Differential binding analysis was performed using DiffBind57 by groping replicates together. 873 
Overlapping peak analysis were performed using intersected from bedtools58. The statistical analysis 874 
of the overlapping peaks were performed using fisher’s exact test from bedtools. ATAC-Seq in HSPC 875 
was performed in biological triplicates, ATAC-Seq experiments for remodelers were performed in 876 
biological duplicates.  877 
GEO accession codes for publicly available data sets 878 
GATA2, GSM552234; CHD4, GSM1296403 and GSM1296404; BRG1, GSM1296402.  879 
Preparation of IP samples for MS 880 
107 416B cells were lysed in the whole cell lysis buffer (50 mM Tris-HCl pH=8, 150 mM NaCl, 0.1% NP-881 
40, 1 mM EDTA), supplemented with 1 mM DTT, protease inhibitors (Sigma), and phosphatase 882 
inhibitors (Sigma). Cell were homogenized and lysate cleared by centrifugation. UTX 883 
immunoprecipitation was performed in the whole cell lysis buffer with 16 ug of antibody bound to 884 
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100ul of Dynabeads Protein G (Thermo Fisher Scientific) and incubated for 1,5h at 4°C with rotation. 885 
IP was washed five times with IP wash buffer (10 mM Tris-HCl pH=8, 150 mM NaCl, 0.1% NP-40, 1 886 
mM EDTA), supplemented with protease inhibitor (Sigma). UTX immunoprecipitates were eluted by 887 
boiling in 1x LDS loading buffer, reduced with 5 mM TCEP, alkylated with 10 mM iodoacetamide and 888 
electrophoresed in Novex NuPAGE Bis-Tris 4%–12% gels (Life Technologies). Gels were stained with 889 
colloidal Coomassie (Sigma). Whole lanes were cut in slices and samples processed for MS analysis as 890 
described previously65.  891 
Sample preparation and LC-MS/MS analysis 892 
The affinity purified material was electrophoresed in 4-12% Bis-Tris NuPAGE gels (Life Technologies). 893 
Gels were fixed and stained with Coomassie as previously described65. The whole gel lanes were 894 
excised into five sections and IgG bands were discarded. Gel pieces were digested with trypsin and 895 
peptides extracted as previously described65. The peptides were re-dissolved in 0.5% formic acid and 896 
analysed with on-line nano liquid chromatography (Ultimate 3000 RSLCnano System) tandem mass 897 
spectrometry on an LTQ Orbitrap Velos mass spectrometer. The sample was desalted on a PepMap 898 
C18 nano-trap (100 µm i.d. x 20 mm, 100Å, 5µm), then separated on a PepMap RSLC C18 column (75 899 
µm i.d. x 250 mm, 100 Å, 2 µm) in a linear gradient of 4-32% CH3CN/0.1% formic acid in 90 mins.  The 900 
HPLC, columns and mass spectrometer were all from Thermo Fisher Scientific. The Orbitrap mass 901 
spectrometer was operated in the standard “top 15” data-dependent acquisition mode while the 902 
preview mode was disabled. The MS full scan was set at m/z 380 – 1600 with the resolution at 903 
30,000 at m/z 400 and AGC at 1x106 with a maximum injection time at 200 msec. The siloxane ion at 904 
445.120030 was used as lock mass.  The 15 most abundant multiply-charged precursor ions (z ≥ 2), 905 
with a minimal signal above 3000 counts, were dynamically selected for CID (Collision Induced 906 
Dissociation) fragmentation in the ion trap, which had the AGC set at 5000 with the maximum 907 
injection time at 100 msec. The precursor isolation width was set at 2 Da.  The normalized collision 908 
energy for CID MS/MS was set at 35%. The dynamic exclusion duration time for the selected ions for 909 
MS/MS was set for 60 sec with ±10 ppm exclusion mass width.  910 
MS data analysis 911 
Raw MS files were processed with Proteome Discoverer v 1.4 (ThermoFisher Scientific). Database 912 
searches were performed using Mascot (v 2.5, Matrix Science) with the mouse Swiss-Prot database 913 
(December 2015, 16942 sequences) supplemented with an in-house contaminant database. The 914 
search parameters were as follow: trypsin digestion, 2 missed cleavages, 10 ppm mass tolerance for 915 
precursor ions, 0.5 Da mass tolerance for fragment ions, variable modifications of carbamidomethyl 916 
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(C), N-acetylation (protein), formyl (N-term), oxidation (M), deamidated (NQ), and pyro-glu (N-term 917 
Q). Database search results were further processed with Percolator66-68 within Proteome Discoverer. 918 
Protein identification required at least one high-confidence peptide (FDR < 1% based on q-value) and 919 
a minimum Mascot protein score of 20. Protein lists for bait and control experiments (2 and 3 920 
replicates respectively) were compared using SAINTexpress with default settings69. External 921 
contaminants were removed for further analysis. Preys with SAINT probability score ≥ 0.99 are 922 
reported in the final high confidence interactors list. The complement protein C1qc was manually 923 
removed from the list because, despite having a SAINT probability of 1, it was detected with a very 924 
similar number of peptides in both bait and control samples (TableS15, TableS16).  925 
Exome sequencing  926 
DNA from 7 Utx-/- AML cases and matched normal DNA extracted from tail tips before pIpC-mediated 927 
Utx deletion, was extracted using DNeasy blood & tissue kit (Qiagen) according to the 928 
manufacturer’s instructions. The extracted DNA was quantified (using Invitrogen’s dsDNA Quant-IT 929 
PicoGreen), followed by normalizing each sample to 4.17ng/ul in 120ul in preparation for library 930 
creation. The first step of library preparation involved shearing the DNA into fragments of 150bp 931 
(using the Covaris LC220 and Agilent Bravo automated workstation for liquid handling) followed by 932 
library creation and PCR using unique index tags and adaptors (Agilent’s SureSelectXT Automated 933 
Library Prep and Capture Kits and MJ Tetrad). The amplified libraries were then purified (using 934 
Agencourt AMPure XP and a Beckman Coulter Biomek NX96 for liquid handling) and eluted in 935 
nuclease-free water followed by another round of quantification (using the Caliper GX). The 936 
quantified, size-selected libraries were then diluted down to an appropriate concentration for 937 
introduction into the exome capture stage. Exome pulldown (or hybridisation) was performed using 938 
Mouse-All Exon RNA-baits (designed by Agilent, supplier ID: S0276129) for 23 hours at 65ºC. Eight 939 
uniquely indexed samples were baited and captured in a single pool as part of the agreed 940 
multiplexing strategy. The pulldown was then purified and eluted using streptavidin-coated Dynal 941 
beads ready to be amplified using PCR (MJ Tetrad). The PCR was then further purified using 942 
Agencourt AMPure XP (and Beckman Coulter Biomek NX96 for liquid handling), followed by 943 
quantification of the amplified pulldown product using the Agilent Bioanalyser. Samples were exome 944 
sequenced as paired-end 75bp inserts using Illumina HiSeq v4 flow-cell chemistry. 945 
Exome data analysis 946 
Somatic variants (point mutations and indels) were called using the Caveman70 and Pindel71,72 947 
pipelines respectively, and filtered for artefacts (including sufficient tumor fraction, strand bias, 948 
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presence of tumor allele in the normal, presence of tumor allele in panel of normal samples also 949 
sequenced at Sanger). Genome-wide copy number variation was called using the Control Freek73 950 
software package. This packages accepts paired tumor/ normal sequence files. We noticed that in a 951 
few of our samples that the sequenced paired normal displayed an artifactual noisiness in 952 
sequencing depth and opted  to use a single ‘quiescent’ normal (MD5280a) as a constant 953 
comparator for all samples.  Control Freek was run using these parameters: step=1000000, 954 
window=5000000, breakpointtype=4, breakpointthreshold=1.2, readcountthreshold=50. The copy-955 
number plots show the normalised bam depth-ratio as produced by ControlFreek (black points), as 956 
well as a mark (red points) for regions marked with CopyNumber = 2. Copy-number variation looking 957 
for a focal change at exon 3 of Utx was run (as before) with an unmatched normal - MD5280a - as 958 
well as the following parameters: step=250, window=500, breakpointthreshold=0.6, 959 
breakpointtype=4, readcountthreshold=50.  960 
Statistical analysis 961 
All statistical analyses were performed using two-sided Student’s T test or one-way ANOVA as 962 
specified in figure legends. Error bars represent the standard error of the mean (s.e.m.) or the 963 
standard deviation (s.d.). P values ≤ 0.05 were considered statistically significant. Representative 964 
data/images were replicated in at least three independent experiments as specified in the relevant 965 
figure legend. Hypergeometric distribution was calculated with the online tool, GeneProf. The 966 
number of independent experiments used to generate statistically significant data is defined in the 967 
relevant figure legends.  968 
URLs 969 
TopHat version 2.0.13 (http://ccb.jhu.edu/software/tophat/)  970 
BioMart data mining tool (http://www.ensembl.org/info/data/biomart/).  971 
GenomicAlignments version 1.2.2 972 
(http://bioconductor.org/packages/3.0/bioc/html/GenomicAlignments.html) with mode="Union". 973 
DESeq2 version 1.6.3 (http://bioconductor.org/packages/3.0/bioc/html/DESeq2.html) 974 
UCSC Genome Browser (http://genome.ucsc.edu/) 975 
BioVenn tool (http://www.biovenn.nl/) 976 
Hypergeometric test, (https://www.geneprof.org/GeneProf/tools/hypergeometric.jsp) 977 
Data Accessibility Statement 978 
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All sequencing and proteomic raw data have been deposited in public repositories. There are no 979 
restrictions to data access. ChIP-Seq and ATAC-Seq data are deposited under accession numbers: 980 
GSE86490 and GSE101307. The exome sequencing data was deposited in ENA under accession 981 
number ERP017908.  MS data are available via ProteomeXchange with identifier PXD005011. For 982 
RNA-Seq data raw files are deposited in ENA: http://www.ebi.ac.uk/ena. Processed RNA-Seq data 983 
are accessible from: 984 
ftp://ngs.sanger.ac.uk/production/casm/2018/Gozdecka_et_al_NatGenet/UTX_FPKM_RNAseq/. 985 
Description of raw and processed RNA-Seq file is provided in the TableS31. 986 
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